
News|Articles|November 15, 2012
Testimony: FDA Commissioner says FDA has limited authority over compounding pharmacies to prevent meningitis outbreak
FDA Commissioner Margaret Hamburg was asked if the fungal meningitis outbreak could have been prevented by FDA during a 4-hour hearing Nov. 14 headed by the chairman of the House Energy and Commerce oversight subcommittee. Her answer was that FDA had limited authority because the New England Compounding Center (NECC), Framingham, Mass., was a ?compounding pharmacy,? which is regulated by the state Board of Pharmacy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HaVy Ngo-Hamilton, Pharm.D. | 2026 MHE Emerging Leaders in Healthcare
2
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2026
3
Sham Firdausi, M.P.H., M.Sc., MBA | 2026 MHE Emerging Leaders in Healthcare
4
FDA clears Amneal’s ready-to-use romidepsin, filling gap left by Teva’s withdrawal
5

























